- Trial phase
- Phase 3 (registrational)
- Time to market
- If Phase 3 RESTORE succeeds, a potential FDA submission could occur in 2028-2029, assuming enrollment completes and the 16-week treatment period yields positive results. Breakthrough Therapy designation may accelerate FDA review.
- Why 4/10
- The next hard dated catalyst is the Phase 3 RESTORE registrational study topline data readout. Since the first patient was dosed in October 2026 and the study is a 16-week treatment period, topline data is likely 12-18+ months away, placing this in the 3-5 impact range for a single-asset company.
The next major catalyst is the Phase 3 RESTORE topline data readout, likely in late 2027 or 2028 given enrollment just began in October 2026. Positive data would validate NVG-291 as a first-in-class neuroreparative therapy for a large unmet need with no approved pharmacologic alternatives; negative data would be devastating for this single-asset company. Interim enrollment updates or any early efficacy signals could also move the stock.
Price Chart
Executive Summary
NVG-291 is a first-in-class therapeutic peptide from NervGen Pharma Corp. (Nasdaq: NGEN) designed to promote nerve repair in spinal cord injury by blocking the CSPG-PTPsigma pathway, a natural brake on nerve regeneration. The drug recently received FDA Breakthrough Therapy designation (November 12, 2026) based on positive Phase 1b/2a CONNECT SCI data showing functional hand use improvements in chronic spinal cord injury patients. A Phase 3 registrational study (RESTORE) began dosing its first participant in October 2026, targeting roughly 150 participants with chronic cervical motor-incomplete spinal cord injury. NervGen is a single-asset company with a market cap around $150M, raised US$60M in May 2026 to fund development, and has analyst support (7 Buy-equivalent ratings). The next major catalyst is the Phase 3 topline readout, likely 12-18+ months away.
How It Works
NVG-291 is a synthetic peptide (a short chain of amino acids) that mimics a part of a naturally occurring protein called phosphatase sigma. It works by blocking a natural "stop signal" in the body that normally prevents nerve cells from regenerating after injury to the brain or spinal cord. By blocking that stop signal, NVG-291 allows damaged nerves to repair themselves, potentially restoring function such as hand use and movement in people with chronic spinal cord injury.
Trial Status
Phase 1b/2a CONNECT SCI study (NCT05965700) completed with positive topline data from the chronic cohort. Phase 3 RESTORE registrational study began dosing first participant in October 2026, targeting ~150 participants with chronic cervical motor-incomplete spinal cord injury across US and Canada. The 16-week study uses change from baseline in GRASSP Quantitative Prehension at Week 12 as the primary endpoint.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 RESTORE study enrollment updates (ongoing, no specific dates announced)
- Phase 3 RESTORE topline data readout (likely late 2027 or 2028, 12-18+ months away)
- Potential additional regulatory milestones under Breakthrough Therapy designation
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NervGen Pharma Corp. Press Release NGEN ·Originating report